Thailand Medical Device Regulations: The Three-Layer Legal Framework

1. Key takeaways

Thai medical device regulation is built in three layers, and all three must be read together. The first layer is the statute itself, the Medical Device Act B.E. 2551 (2008), which supplies the definition of a medical device in Article 4, the authorisation for classification, the establishment licensing regime and the penalty provisions, including the advertising penalty in Article 116. The second layer is the amendment, the Medical Device Act (No. 2) B.E. 2562 (2019), which introduced the current four-class risk system running from Class 1 to Class 4 together with three registration pathways, and which revised the defect and adverse event reporting obligation in Article 41 paragraph 4 as well as the mandatory recall power of the Secretary-General in Article 55 paragraph 5. The third layer consists of MoPH Notifications and Thai FDA announcements that supply the operational detail.

• Layer one, the law: Medical Device Act B.E. 2551 (2008), with device definition in Article 4, classification authorisation, licensing and penalties such as the advertising sanction in Article 116.
• Layer two, the amendment: Medical Device Act (No. 2) B.E. 2562 (2019), introducing risk Classes 1 to 4 and three registration pathways, revising reporting duties under Article 41 paragraph 4 and the Secretary-General recall power under Article 55 paragraph 5.
• Layer three, notifications and guidance: MoPH Notifications on classification (B.E. 2562), vigilance (B.E. 2563, that is 2020), GMP (B.E. 2566, that is 2023) and labelling (B.E. 2568, that is 2025), plus Thai FDA announcements.
• The most common failure in practice is citing only the parent Act and thereby inheriting outdated terminology, missing amended reporting duties and missing vigilance timelines.
• The Thai FDA English website is the primary first-hand source for the full process, official fees and document checklists.

2. Legal basis

Why must all three instruments be read together rather than the parent Act alone? Because the most frequent error observed in practice is citing only the Medical Device Act B.E. 2551 in its original form. Three concrete traps follow from that habit. First, citing only the parent Act means inheriting the old three-tier classification nomenclature that the amendment Act B.E. 2562 replaced, so the document ends up describing a framework that no longer exists. Second, citing only the parent Act misses the defect and adverse event reporting obligations as revised in Article 41 paragraph 4 by the amendment, so the reporting duties that actually bind the licence holder today are overlooked. Third, citing only the parent Act misses the vigilance timeline structure set by the B.E. 2563 vigilance notification, namely 48 hours, 10 days and 30 days for different categories of reports, which the parent Act itself does not contain, and which therefore cannot be derived from the statute alone in any circumstance.

The Buddhist Era calendar also belongs in any account of the legal basis. Thai legislation is drafted exclusively in B.E. years, and the conversion is B.E. minus 543 equals the Gregorian year. The practical consequence of ignoring this is a systematic misjudgment of urgency. For example, the B.E. 2568 labelling notification, which is 2025, is easily misread as a distant future instrument; in reality it took effect on 20 June 2026. A reader who does not convert the era would underestimate how binding and how current these requirements already are.

3. Expert insights

There is a practical reason to make the Thai FDA website the primary lookup source rather than any secondary commentary. The English pages publish the complete regulatory walkthrough from classification to certification, organised as Steps 1 to 7, together with the consolidated official fee schedule and the document checklist matrix. That matrix compares, item by item, the Full, Abridged and Reliance pathways for Class 1 devices and for Class 2 to 4 devices, which is exactly the comparison a submission planner needs. These are first-tier sources: they carry more weight than any secondary interpretation, and the fee and document figures used throughout this series are benchmarked against them. In other words, where any commentary conflicts with the official pages, the official pages win. A second insight concerns internal consistency. The gap between what a sales team promises, what a regulatory team files and what a logistics team assumes usually originates from each team quoting a different instrument of the three-layer framework. The remedy is a single shared reference rather than three private ones, maintained once and reused company-wide.

4. Practical recommendations

• Build an article-to-notification mapping ledger that records, for each frequently used provision, the current authoritative text: Article 4 definitions, Article 27 exemptions, Article 41 reporting obligations, Article 55 mandatory recall and Article 116 advertising penalties.
• Record both the Buddhist Era year and the Gregorian year side by side in that ledger, so no reader ever needs to perform the conversion mentally.
• Never cite the Medical Device Act B.E. 2551 alone; whenever a provision was touched by the amendment Act B.E. 2562, cite the amended text.
• Anchor fee and checklist questions in the Thai FDA official pages covering Steps 1 to 7, the fee schedule and the Full, Abridged and Reliance document matrix, rather than in marketing summaries.
• Share the ledger across regulatory, sales and logistics functions so that all three teams work from one version of the framework.

5. Verification checklist

• □ Medical Device Act B.E. 2551 (2008), Articles 4, 27, 41, 55 and 116 confirmed (pending verification against the statute text).
• □ Medical Device Act (No. 2) B.E. 2562 (2019), amended content confirmed (pending verification).
• □ MoPH risk classification notification B.E. 2562, Government Gazette 18 December 2019 (pending verification).
• □ MoPH notification on device defect, adverse event and FSCA reporting B.E. 2563 (2020) (pending verification).
• □ MoPH labelling and accompanying documents notification B.E. 2568 (2025) (pending verification).
• □ Thai FDA website For Commercial Purpose process page (pending verification).

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Thailand. Our team prepares dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with the Thai FDA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com